. Author manuscript; available in PMC: 2015 Feb 1.

Published in final edited form as: Lancet Infect Dis. 2014 Jul 3;14(8):687–695. doi: 10.1016/S1473-3099(14)70779-0

Table 2.

Cysticidal efficacy by treatment group and number of cysts

	Albendazole plus praziquantel (n=39)	Standard albendazole (n=41)	Increased albendazole (n=38)	Overall p value
One to two cysts

Viable cysts at baseline	27	22	23	0·284
Mean per patient (SD)	1·4 (0·6)	1·1 (0·3)	1·3 (0·6)	0·281
Cyst range	1–3^*	1–2	1–3^*	..
Number of patients	20	20	18	..
Viable cysts at day 180	10	6	3	0·237
Mean per patient (SD)	0·5 (07)	0·3 (0·5)	0·2 (04)	0·162
Cysts resolved	17/27 (63%)	16/22 (73%)	20/23 (87%)	0·141
Patients cured	12/20 (60%)	14/20 (70%)	15/18 (83%)	0·287

Three or more cysts

Viable cysts at baseline	171	142	142	0·179
Mean per patient (SD)	9·0 (4·8)	6·8 (4·2)	7·1 (44)	0·245
Cyst range	3–19	3–18	3–18	..
Number of patients	19	21	20	..
Viable cysts at day 180	11	112	74	<0·0001
Mean per patient (SD)	0·6 (1·0)	5·3 (4·2)	3·7 (3·1)	0·0001
Cysts resolved	160/171 (94%)	30/142 (21%)	68/142 (48%)	<0·0001
Patients cured	13/19 (68%)	1/21 (5%)	5/20 (25%)	<0·0001

Data are n/N (%), unless otherwise indicated.

In each of these groups, an additional cyst was identified in the MRI of one patient after they had been randomised in the one to two cysts stratum.